# Immunocore Holdings plc American (IMCR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $36.13, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Immunocore Holdings plc American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 4.3×**. Each dollar of revenue is priced at 4.3×.
- **Price / book: 4.4×**. The shares trade at 4.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -2.2%** (5-yr avg -2.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -5.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -8.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -9.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: -1.7%**. Each dollar of assets produces -1.7% of profit.

## Growth
- **Revenue growth (1 yr): 29.0%** (3-yr 31.9%/yr). Revenue grew 29.0% over the last year.
- **EPS growth (1 yr): 30.4%**. Earnings per share rose 30.4%, roughly in step with revenue.

## Financial health
- **Current ratio: 4.04** (quick 4.04). Current assets cover the next year's liabilities 4.04 times.
- **Altman Z-score: 3.20**. A Z-score of 3.20 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Immunocore Holdings plc American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Immunocore Holdings plc American; the consensus is strong_buy, with an average price target of $62.50 (+73% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 2.5%** (YTD 4.1%, 3-mo 27.7%). The shares are up 2.5% over twelve months including dividends.
- **From 52-week high: -11.3%** (31.1% above the low). Trading 11% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.62** (volatility 38%). Beta of 0.62 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IMCR · Page: https://foliofundamentals.com/stocks/imcr

Not investment advice.